Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Robert Reis to Multiple Myeloma

This is a "connection" page, showing publications Robert Reis has written about Multiple Myeloma.

 
Connection Strength
 
 
 
0.460
 
  1. Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ. Genomic Instability in Multiple Myeloma. Trends Cancer. 2020 10; 6(10):858-873.
    View in: PubMed
    Score: 0.130
  2. Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Mol Cancer Ther. 2016 Feb; 15(2):241-50.
    View in: PubMed
    Score: 0.096
  3. Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biol Ther. 2015; 16(6):976-86.
    View in: PubMed
    Score: 0.092
  4. Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009 Mar 05; 113(10):2290-7.
    View in: PubMed
    Score: 0.059
  5. Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6.
    View in: PubMed
    Score: 0.042
  6. Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003 Sep; 2(9):825-33.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.